

Special Issue

Recent Advances in Endometrial Cancer Prevention, Early Diagnosis and Treatment

Message from the Guest Editor

The rising global incidence of endometrial cancer means that more women than ever are living with and, unfortunately, also dying from the disease. Whilst surgery in combination with radio- and chemotherapy has long been the cornerstone of endometrial cancer treatment, increasing knowledge of endometrial cancer biology has ensured the success of fertility-sparing approaches and enabled the personalisation of care. The molecular characterisation of tumours and clinical trials of immunotherapies are set to revolutionise how we manage the disease as we move towards improving disease control whilst minimising the side effects of treatment. This Special Issue aims to highlight recent advances in the prevention, early diagnosis and treatment of early and advanced/recurrent endometrial cancer, and to answer outstanding research questions. Both original research articles and review papers are welcome.

Guest Editor

Dr. Sarah J. Kitson

Division of Cancer Sciences, The University of Manchester,
Manchester, UK

Deadline for manuscript submissions

closed (23 February 2024)



Cancers

an Open Access Journal
by MDPI

Impact Factor 4.4
CiteScore 8.8
Indexed in PubMed



mdpi.com/si/133691

Cancers
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
cancers@mdpi.com

[mdpi.com/journal/
cancers](https://mdpi.com/journal/cancers)





Cancers

an Open Access Journal
by MDPI

Impact Factor 4.4
CiteScore 8.8
Indexed in PubMed



[mdpi.com/journal/
cancers](https://mdpi.com/journal/cancers)



About the Journal

Message from the Editor-in-Chief

Cancers is an international online journal addressing both clinical and basic science issues related to cancer research. The journal is publishing in Open Access format, which will certainly evolve to ensure that the journal takes full advantage of the rapidly changing world of information and knowledge dissemination. It publishes high-quality clinical, translational, and basic science research on cancer prevention, initiation, progression, and treatment, as well as other related topics, particularly to capture the most seminal studies in the rapidly growing area of immunology, immunotherapy, and tumor microenvironment.

Editor-in-Chief

Prof. Dr. Samuel C. Mok

Department of Gynecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA

Author Benefits

Open Access:

free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPus / SciFinder, and other databases.

Journal Rank:

JCR - Q2 (Oncology) / CiteScore - Q1 (Oncology)